

# ***In silico* cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome**

Jeroen Creemers<sup>1,2</sup>, Ankur Ankan<sup>3</sup>, Kit C.B. Roes<sup>4</sup>, Gijs Schröder<sup>3</sup>, Niven Mehra<sup>5</sup>, Carl G. Figdor<sup>1,2</sup>, I. Jolanda M. de Vries<sup>1</sup>, Johannes Textor<sup>1,3#</sup>

<sup>1</sup> Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>2</sup> Oncode Institute, Nijmegen, The Netherlands

<sup>3</sup> Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands

<sup>4</sup> Department of Health Evidence, Section Biostatistics, Radboudumc, Nijmegen, The Netherlands

<sup>5</sup> Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands

Corresponding author email address:

#[johannes.textor@ru.nl](mailto:johannes.textor@ru.nl)

## **Abstract**

Late-stage cancer immunotherapy trials often lead to unusual survival curve shapes, like delayed curve separation or a plateauing curve in the treatment arm. It is critical for trial success to anticipate such effects in advance and adjust the design accordingly. Here, we use *in silico* cancer immunotherapy trials – simulated trials based on three different mathematical models – to assemble virtual patient cohorts undergoing late-stage immunotherapy, chemotherapy, or combination therapies. We find that all three simulation models predict the distinctive survival curve shapes commonly associated with immunotherapies. Considering four aspects of clinical trial design – sample size, endpoint, randomization rate, and interim analyses – we demonstrate how, by simulating various possible scenarios, the robustness of trial design choices can be scrutinized, and possible pitfalls can be identified in advance. We provide readily usable, web-based implementations of our three trial simulation models to facilitate their use by biomedical researchers, doctors, and trialists.

## 1 Introduction

2 Immunotherapy is revolutionizing the treatment landscape for patients with advanced cancers. While the number of  
3 immuno-oncology drugs under investigation is rising rapidly – around 4700 agents are currently in the development  
4 pipeline – the need to further improve patient outcomes remains high [1]. Well-designed immunotherapy trials are cru-  
5 cial to establish advances in clinical outcomes robustly. Unfortunately, the odds for cancer treatments to successfully  
6 pass the development pipeline are unfavorable, and only a minority of the treatments (5-10%) ultimately obtain market  
7 approval [2–4]. Even for cancer therapies that do reach late-stage development, approval rates remain modest at around  
8 27% [5]. The primary reason in most of these trials (i.e., 63.7%) is failure to demonstrate efficacy [5], which can be  
9 partly attributed to suboptimal trial design choices based on overly optimistic assumptions of the treatment effect. Such  
10 assumptions may be used to erroneously justify low numbers of patients or inappropriate endpoints and lower the power  
11 of these trials [5, 6].

12 Immunotherapy trials raise complex design questions, and conventional design methods are not always a good match to  
13 the unique characteristics of immunotherapies [7]. There is a very broad spectrum of therapies based on various molecular  
14 mechanisms – ranging from immunomodulators to cell therapies, cancer vaccines, oncolytic viruses, and CD3-targeted  
15 bispecific antibodies – that can lead to unusual toxicity profiles, response patterns, and survival kinetics [8–10]. These ob-  
16 servations render a “one-design-fits-all” approach futile and stress the need for designs that are tailored to immunotherapy  
17 or even combination therapies.

18 Immunotherapies are known to induce a delayed clinical effect and long-term overall survival (OS) in only a subset of  
19 patients [11]. The survival curve reflects these phenomena by a delayed curve separation and a plateau of the treatment  
20 arm at later stages of the trial [12]. These characteristics violate a fundamental premise that underlies the design of many  
21 trials: the proportional hazard assumption (PHA) – essentially stating that the treatment effect should remain constant over  
22 time [13]. As a result, immunotherapy trials based on this principle can have an overestimated power [12, 13] and require  
23 a longer follow-up to demonstrate efficacy than initially planned [12], increasing the likelihood of a negative trial.

24 These issues led to the development of innovative methods such as novel radiological criteria to quantify tumor responses  
25 [9, 14, 15], (surrogate) endpoints to capture unique survival kinetics [10, 16–19], biomarkers to enrich for patients more  
26 likely to respond to treatment [20–23], and statistical methods to retain a trial’s power in the presence of unusual survival  
27 kinetics [24–26]. Despite the multitude of available methods, it is difficult to predict trial outcomes in advance and select  
28 the methodology accordingly. The stakes are high: a trial design built on accurate predictions of the response kinetics is  
29 more likely to be positive, whereas misjudgment could result in a negative trial, potentially compromising patient benefit,  
30 vast amounts of work, and (public) research funds.

31 In this study, we use late-stage *in silico* cancer immunotherapy trials to investigate how design decisions affect the trial  
32 outcome in the context of cancer immunotherapy, possibly combined with chemotherapy. The mechanism-based nature  
33 of these trials allows researchers to translate cellular processes in the tumor microenvironment and immunotherapeutic  
34 interventions thereon into predicted response patterns, survival kinetics, and trial outcomes. An *in silico* immunotherapy  
35 trial is based on explicit biological assumptions and provides an intuitive means to predict risk profiles and treatment  
36 efficacy. Moreover, it equips researchers with a tool to scrutinize trial designs and analysis strategies of upcoming trials  
37 in advance to identify potential risks and pitfalls.

38 We use three different simulation models to perform our *in silico* trials, based on work by ourselves [27] and other au-  
39 thors [28, 29]. Despite considerable differences, all models replicate late-stage immunotherapy or combination trials  
40 reasonably well and capture their typical survival kinetics. Then, we demonstrate various applications of such trial simu-  
41 lations, including the ability to scrutinize a clinical trial’s design and sample size calculations based on a range of predicted  
42 possible outcomes. Finally, we illustrate the consequences of (not) considering immunotherapy-specific response patterns  
43 in settings selected for educational purposes, such as selecting survival endpoints and randomization ratios of upcoming  
44 trials and planning interim analyses.

## 45 Results

### 46 Generating trial populations based on tumor-immune dynamics

47 We used *in silico* cancer immunotherapy trials based on mechanistic simulations of cancer-immune dynamics to investigate  
48 the consequences of immunotherapy-specific response patterns on trial design principles [26]. The virtual patients in these  
49 trials are simulated with ODE models, which describe disease courses based on assumptions about interactions between  
50 tumor cells and the immune system [26]. In this paper, we will focus on simulating two years of follow-up after treatment  
51 – while it is straightforward to consider longer follow up times with *in silico* trials, a two-year time frame is common for  
52 contemporary immunotherapy trials [30–32].


53 To investigate the extent to which our simulation results depend on specific modeling choices, we use three different ODE  
54 models. Model 1 (M1) describes the following tumor-immune dynamics in the tumor microenvironment: immunogenic  
55 tumor growth leading to priming and clonal expansion of naïve T cells, migration of effector T cells to the tumor microen-  
56 vironment, and formation of tumor-immune complexes to enable tumor cell killing (see Methods; Figure 1A). We simulate  
57 treating these patients with immune checkpoint inhibitors (ICI), chemotherapy, or both. ICI increase the T cell killing rate  
58 and directly affect the tumor-immune dynamics. Chemotherapy has a cytotoxic effect on the tumor, slowing its growth. A  
59 detailed description of the model, including the rationale for parameter selection, has been published previously [26]. In  
60 contrast, model 2 (M2) does not represent T cells migration between lymph nodes and tumor microenvironment; however,  
61 it does contain an explicit representation of antigen-presenting cells (APCs) [33]. Finally, Model 3 (M3) does not contain  
62 either T cell migration or APCs, but it does take T cell exhaustion into account. Another important difference between  
63 the models lies in how tumor growth is represented: M1 uses a size-dependent growth rate, M3 a resource-constrained  
64 growth rate (logistic growth), and M2 uses unlimited exponential growth.

86 Regardless of model specifics, *in silico* clinical trials describe cancer outcomes on three levels: (1) a cellular level, (2)  
87 a patient level, and (3) a trial population level. Cellular interactions in the tumor microenvironment are translated into  
88 clinical trial outcomes as follows: firstly, the ODE model is implemented, and model parameters that vary between patients  
89 are selected by fitting to existing survival data (Figure 1B; see Methods). Next, individualized disease trajectories –  
90 either treated or untreated – of cancer patients are generated (Figure 1C). Eventually, patients are randomized into two  
91 cohorts to resemble conventional phase III trials: a control group (either placebo or chemotherapy) and a treatment group  
92 (immunotherapy, chemoimmunotherapy, or induction chemotherapy followed by immunotherapy; Figure 1D). Since the  
93 cellular dynamics (e.g., tumor burden over time or the efficacy of T cell killing) and survival outcomes of these patients are  
94 known and can be modified, *in silico* clinical trials are suited to answer questions like: “Assuming that a novel treatment  
95 increases T cell killing 5-fold, how does this translate to a survival benefit in patients? Moreover, how many patients are  
96 needed to establish this benefit in a clinical trial? When should one analyze the results?” (Figure 1E).


97 Despite their differing mechanisms, the models generate qualitatively similar predictions (Figure 2): tumors grow at real-  
98 istic speeds and are usually not cleared by the immune system without therapeutic intervention. In the models, therapeutic  
99 interventions can slow or even reverse tumor growth, in principle leading to two major contrasting outcomes: death or  
100 long-term survival. However, there is a unique effect in M3 where even after treatment and growth reverse, the tumor  
101 burden keeps oscillating over time, leading to regular self-resolving recurrences. While this may not be entirely realistic,  
102 it is not an issue for our purpose as we shall focus on the initial growth trajectory of the tumor preceding and up to 2 years  
103 after treatment, and recurrences happen after that.

### 104 *In silico* late-stage immunotherapy trials yield realistic survival outcomes


105 To investigate whether our *in silico* models can generate realistic survival curves as observed in late-stage immunotherapy  
106 trials, we fitted the models to three different datasets: (1) the NCCTG lung cancer survival dataset [34]; (2) the CA184-024  
107 trial (ipilimumab + dacarbazine vs. dacarbazine in previously untreated metastatic melanoma [35]); and (3) the CheckMate  
108 066 trial (nivolumab + placebo vs. dacarbazine + placebo in treatment-naïve metastatic melanoma patients without BRAF  
109 mutation [36]). The choice for these trials is based on the size of the trials and the maturity of the data. The follow-up  
110 of the CA184-024 trial and the CheckMate 066 trial were five and three years, respectively. As the last two datasets  
111 were not publicly available, we extracted the data using image digitization (see Methods). As a reference for the *in silico*  
112 trials, we visualized the Kaplan-Meier estimators of these datasets (Figure 3A). Both trials were digitized correctly, as  
113 reflected by the nearly identical risk tables compared to the original manuscripts [35, 36]. Next, we fitted the tumor  
114 growth rate distributions and treatment effect parameters for chemotherapy and immunotherapy s (NCCTG: 3 parameters;  
115 immunotherapy trials: 4 parameters) to these datasets (M1: Figure 3B; M2, M3: Supplementary Figure S1). For the  
116 CA184-024 and CheckMate 066 trials, the simulated patients were treated with ICI upon diagnosis, increasing their T cell  
117 killing rates. For simplicity, we did not simulate dropout or censoring in the trials shown in this paper, although it could  
118 be added to the simulation. Model M1 achieved satisfactory fits to all datasets. However, M2 and M3 had difficulties  
119 fitting the CheckMate 066 data, with M2 predicting more rapid death in the control arm and M3 predicting a cross-over  
120 of survival curves. M3 also had difficulties fitting the other two datasets, as its survival curves plateaued from 12 months



65 Figure 1: ***In silico* late-stage immunotherapy trials and their applications** (A) Cellular interactions between a tumor  
 66 and the immune system as implemented in ODE model M1 (Methods). This model describes immunogenic tumor growth  
 67 leading to a T cell response originating from lymph nodes. Disease courses in patients can be steered by immunotherapy,  
 68 chemotherapy, or a combination of both. Parameters:  $\alpha$  = naive T cell priming rate,  $\delta$  = effector T cell death rate,  $\xi$  =  
 69 effector T cell killing rate,  $\rho$  = tumor growth rate,  $\rho_s$  = effector T cell proliferation rate, and  $m_s$  = effector T cell migration  
 70 rate. (B) After implementation, we used survival data from clinical trials to fit some of the model parameters. (C) Patients  
 71 received either no treatment (placebo), chemotherapy, immunotherapy, or both. Disease trajectories based on tumor-  
 72 immune dynamics were simulated for each patient, resulting in individual survival outcomes. (D) Subsequently, cohorts  
 73 of patients were constructed based on the fitted parameters to simulate actual immunotherapy trials. (E) Applications  
 74 of such trials include predicting possible survival outcomes of trials, estimating sample sizes needed for a range of scenarios,  
 75 and investigating endpoints, randomization ratios, and the timing of interim analyses.



76  
 77 Figure 2: **Simulating immunotherapy responses using different mathematical models.** Each simulation starts with a  
 78 single malignant cell that establishes a tumor. Without treatment, this tumor grows to a lethal volume (upper horizontal  
 79 line) over the course of several months. Treatment is started when the tumor reaches a size of  $65 \times 10^8$  cells (lower  
 80 horizontal line). Immunotherapy is implemented in each model by increasing the rate at which T cells kill tumor cells;  
 81 in M2, the death rate of T cells is additionally decreased by the same factor. The treatment effect sizes are chosen per  
 82 model such that there is a partial response (orange, leading to prolonged survival) or a complete response (red, leading to  
 83 tumor eradication). The recurrence of the tumor in M3 is a consequence of the model's equations, which lead to oscillating  
 84 dynamics of the tumor burden rather than complete eradication in the complete response regime. Arrows indicate start of  
 85 treatment.



132 **Figure 3: Fitting *in silico* cancer immunotherapy trial models to actual data to simulate realistic survival curves.**  
 133 (A) Kaplan-Meier estimators of the NCCTG, CA184-024, and CheckMate 066 trials. While the NCCTG dataset is publicly available [34], the others are carefully reconstructed survival curves based on digitized data from their respective  
 134 manuscripts [35], [36]. (B) Trial simulations can generate realistic survival curves as observed in actual immunotherapy  
 135 trials. Specifically, typical immunotherapy-related survival curve shapes – such as a delayed curve separation and a plateau  
 136 in the treatment arm – arise from these simulations as emergent behavior.  
 137

121 after treatment onwards. While the fit of all models can be improved by allowing more parameters to vary, we chose to  
 122 keep the number of fitted parameters small to investigate the consequences of such issues on our downstream analyses.

123 Hence, our *in silico* trials couple the disease mechanism and mechanistic treatment effect to a predicted clinical trial  
 124 outcome. By allowing model parameters to vary between patients, such models can be fitted to existing clinical trial data.  
 125 Whether a good fit can be achieved depends on the model assumptions and the number of parameters that are allowed to  
 126 vary. In our case, models M1 and M2 were able to fit the three datasets reasonably well, with M3 showing a substantially  
 127 worse fit.

128 Interestingly, although not incorporated explicitly, the models reproduced hallmark survival curve features arising as a  
 129 consequence of the interaction between tumor and immune cells typically seen in immunotherapy trials: a delayed curve  
 130 separation and a plateau of the survival curve of the treatment arm at later stages of the trial (last two columns in **Figure 3B**  
 131 and **Supplementary Figure S1**).

### 138 ***In silico* immunotherapy trials predict immunotherapy-specific response patterns**

139 The design and the success rate of any clinical trial depends, among others, on a realistic predictions of the shape of  
 140 the survival curves and the distribution of clinical outcomes. For late-stage immunotherapy trials, commonly observed  
 141 immunotherapy-induced response patterns are a delayed curve separation and a plateauing tail of the survival curve of the  
 142 treatment arm (**Figure 3**). These characteristic survival curve shapes violate a vital premise of many clinical trials: the  
 143 proportional hazard assumption (PHA). The PHA states that the “instantaneous death rate” of a patient (i.e., the hazard  
 144 rate) in both arms of the trial should be proportional, resulting in a constant hazard ratio. Many traditional design methods,  
 145 ranging from sample size calculations to outcome analyses, are based on this convenient assumption. For late-stage  
 146 immunotherapy trials, this induces two problems: (1) while a violation of the PHA needs to be addressed during trial  
 147 planning, the hazard rates – and an eventual violation of the PHA – becomes available only after the trial; and (2) if a trial  
 148 does not adhere to a PHA, what will be the shape of the survival curve? Especially in an era where treatment and control  
 149 arm regimens are becoming increasingly complex, adjusting the design and analysis methods to various survival curve



150 shapes is challenging.

151 *In silico* clinical trials can provide principled predictions about possible shapes of the survival curve, including the under-  
152 lying hazard rates and hazard ratios, before trial execution. We generated such survival predictions using the models –  
153 fitted to the CA184-024 data (Table 3) – and changed the treatment effect parameters according to the simulated scenario.

154 A traditional scenario would be a trial in which patients are randomized 1:1 to mono-chemotherapy or placebo. Given the  
155 direct chemotherapy effect, the PHA is generally assumed to hold for these trials. An *in silico* trial in which chemotherapy  
156 reduces the tumor growth rate for the entire trial duration indeed replicates these assumptions (Supplementary Figure S2):  
157 the survival curves separate from the start of the trial, and the hazard ratio remains roughly constant over time. However,  
158 what happens if the chemotherapy effect does not last for the entire trial but for – maybe more realistically – 6 months?  
159 For M1 and M2, the initial proportional separation of the survival curves is followed by a parallel decay and eventual  
160 convergence of both curves, leading to an early but transient survival benefit for the chemotherapy arm (Figure 4A, B).  
161 For M3, the chemotherapy effect estimated from the CA184-024 data is more profound and instead induces a permanent  
162 response (Figure 4C). Hence, substantial deviations from the PHA are observed in all cases, even for seemingly simple  
163 chemotherapy trials. Also, a violated PHA becomes immediately apparent when considering a more contemporary sce-  
164 nario of immunotherapy combined with chemotherapy compared to chemotherapy alone: through approximately the first  
165 six months, the hazard rates remain constant over time, but after that, they start to decline in the immunotherapy group  
166 (cyan line), yielding a non-constant hazard ratio over time (Figure 4D).

167 The flexibility of *in silico* trials lies in their ability to incorporate complex treatment regimens. For example, let us assume  
168 one would be interested in estimating the survival curves and underlying hazard ratio over time of an immunotherapy +  
169 placebo-chemotherapy vs. chemotherapy + placebo-immunotherapy trial (Figure 4E) or a trial with induction chemother-  
170 apy followed by immunotherapy vs. immunotherapy (Figure 4F). Mechanism-based immunotherapy trials translate bi-  
171 ological assumptions regarding the disease and treatment effects into survival curves (including its hazard rate/ratio esti-  
172 mates). The resulting survival curve shapes, such as crossing survival curves (Figure 4E) or a temporary curve separation  
173 (Figure 4F), may be hard to predict otherwise and can be detrimental to the trial outcome if addressed appropriately.


174 We emphasize that different models can generate different predictions depending on model assumptions and parameters,  
175 as seen in our chemotherapy vs. placebo examples (Figure 4A, B, C). Conversely, however, even substantially different  
176 models can agree on the essential aspects of the predicted survival curves. For example, despite their differences, our  
177 three models all predict the characteristic delayed curve separation of immunotherapy trials (Figure 4D, Supplementary  
178 Figure S3, Supplementary Figure S4).

## 191 **Using *in silico* trials to select an appropriate outcome metric for measuring a treatment's clinical** 192 **effect**

193 A key design decision in a clinical trial is which effect size metric to use to define treatment success. Two common choices  
194 are the overall hazard ratio, which is affected by the entire survival data of the trial, and a survival endpoint such as 2-year  
195 overall survival (OS), which only depends on the specifically defined time-point. When there is no solid clinical rationale  
196 to prefer one effect size measure over the other, statistical considerations such as power become important. To investigate  
197 the consequences of choosing hazard ratio or 2-year OS as the study effect size in different immunotherapy scenarios, we  
198 determined the power of *in silico* trials by conducting simulations at varying study population sizes.

199 A potential advantage of using the hazard ratio is its use of the entire survival curve, which can increase power when the  
200 PHA is met and detect transient effects even if the PHA is not met. Indeed, when investigating the power of the transient  
201 chemotherapy effect generated by model M1 (Figure 4A), we found the power to be much greater when using the hazard  
202 ratio compared to the power to detect the minimal difference in survival still found after 2 years. The opposite was true  
203 when investigating the chemoimmunotherapy vs. immunotherapy scenario using M2 (Figure 4B): the power of trials that  
204 used the hazard ratio lagged far behind the power to detect a 2-year survival endpoint, as a consequence of the considerable  
205 violation of the PHA in this scenario. Indeed, when considering the persistent chemotherapy effect generated by model M3  
206 (Figure 4C), a scenario with a substantially lower variation of the hazard ratio, we found the power to be more comparable,  
207 although the hazard ratio still had a meaningful advantage. When using M3 to investigate the chemoimmunotherapy vs.  
208 immunotherapy scenario, the choice of endpoint made hardly any difference (Supplementary Figure S5).

209 These results illustrate the critical importance of choosing an appropriate effect size to measure the clinical outcome, which  
210 in turn strongly depends on the shape of the survival curves. For established treatments, investigators can rely on their  
211 experience or published results to make an appropriate choice; however, the expected survival curve shape might be very  
212 uncertain for novel immunotherapies or combinations of existing immunotherapies. In such cases, running various *in silico*  
213 trials would help investigators prepare for different plausible scenarios and choose a robust trial design. In our examples,  
214 the models agreed that hazard ratio would be a suitable effect size for a chemotherapy vs. placebo trial even if the PHA  
215 does not entirely hold, whereas 2-year OS would be appropriate for the chemoimmunotherapy vs. immunotherapy case  
216 (Supplementary Figure S5).



179 **Figure 4: *In silico* clinical trials can predict immunotherapy-specific survival patterns based on biological assumptions.** (A-F) Examples of 1:1 randomized trials with various (treatment) regimens (n=600 per arm). (A-C) A traditional  
 180 chemotherapy trial (vs. placebo) only shows a proportional hazard ratio when the biological treatment effect targets the tu-  
 181 mor directly and remains constant over time (compare to **Supplementary Figure S2**). (D) An *in silico* immunotherapy trial  
 182 elicits typical immunotherapy-induced survival curve shapes (i.e., delayed curve separation) and violates the proportional  
 183 hazard assumption. (E-F) More intricate treatment or control regimens – (D) immunotherapy + chemotherapy-placebo vs.  
 184 chemotherapy + immunotherapy-placebo, or (E) induction chemotherapy followed by immunotherapy vs. immunother-  
 185 apy – induce more complex survival patterns, including (E) crossing survival curves or (F) only a temporary separation  
 186 of the survival curves. Horizontal bars underneath the survival curves indicate the duration of the treatment effect (T =  
 187 treatment, C = control). The red dot in column three indicates the hazard ratio averaged over the entire trial. Shading:  
 188 95% CIs.  
 189




Figure 5: **Immunotherapy-specific survival curve shapes critically determine a trial’s power to detect different treatment effects.** We analyzed the power of *in silico* trials to detect a difference in 2-year OS (black lines) or a hazard ratio <1 (red lines) for (A) chemotherapy vs. placebo (transient effect, M1); (B) chemoimmunotherapy vs. chemotherapy (M2); and chemotherapy vs. placebo (long-term effect; M3). Choosing an inappropriate effect size for the response pattern at hand leads to a significant reduction in trial power, greatly reducing the probability of success. The chemotherapy effect for M3 was set to a 20% reduction in growth rate to simulate a more subtle effect; all other parameters were set to the values fitted to the CA184-024 data. Error bars: 95% CIs.

### 217 *In silico* trials can help to choose endpoints and randomization ratios before trial execution

218 Clearly, the success rate of novel immunotherapy trials depends on more than its sample size alone. To establish an OS  
 219 benefit of the treatment arm, it is crucial to analyze the trial once the data have reached a certain maturity – i.e., the  
 220 treatment needs to be granted sufficient time to induce a survival benefit. We assumed that a delayed curve separation  
 221 in immunotherapy trials would prolong the follow-up needed to establish an OS benefit of immunotherapy and thereby  
 222 defer reaching maturity of the trial data. If the therapy is effective, data maturity can be regarded as the time point when  
 223 a treatment effect can be observed. Hence, an optimal trial endpoint would be the earliest time at which this treatment  
 224 effect can be detected with sufficient power. Therefore, we analyzed the power of differently sized trials with respect  
 225 to their OS endpoint. Herein, we distinguished trials that were subject or were not subject to a delayed curve separation  
 226 (immunotherapy and chemotherapy, respectively). In a classic chemotherapy trial, the treatment effect translates directly to  
 227 a survival benefit in the treatment arm – the survival curves separate from the start. Therefore, the highest power is obtained  
 228 after the total duration of the treatment effect (Figure 6A, panel 1). In this case, the treatment effect lasts for six months,  
 229 leading to the 6-months OS as the endpoint with the highest power. The delayed curve separation in immunotherapy trials  
 230 renders it futile to analyze OS data early on in the trial (Figure 6B, panel 1). A practical ramification is that in the presence  
 231 of a delayed curve separation, the trial requires a sufficiently long follow-up and an adequate size to gain power and detect  
 232 immunotherapy-specific treatment effects. Mechanism- and simulation-based power calculations with *in silico* trials can  
 233 consider these specific survival curve features when determining the sample size for upcoming trials.


234 Given the observation that both the size of an immunotherapy trial and its endpoint heavily influence the probability of  
 235 finding the survival benefit of interest, we presumed that increasing the size of the treatment arm – i.e., an unequal  
 236 randomization scheme – would similarly affect the power. Instead of varying the study size, we now varied the randomization  
 237 ratio (second panel of Figure 6A/B). Interestingly, while the power logically depended on the OS endpoint, the randomization  
 238 ratio did not greatly affect the power (Figure 6B). Considering that an unequal treatment allocation may provide  
 239 ethical benefits, we confirm that the randomization ratio in immunotherapy trials is of secondary importance compared to  
 240 its size or primary OS endpoint.

241 In summary, our *in silico* immunotherapy trials replicate existing insights from trial design as to how violation of the PHA  
 242 affects power and analysis choices. Our ability to directly translate biological assumptions on treatment mechanisms into  
 243 survival curve shapes allows the trialist to reason deliberately about whether such violations of the PHA would or would  
 244 not be expected in their specific trial design and how the problem could be addressed if it arises.

### 245 Simulating interim analyses to evaluate the trade-off between patient benefit and trial resources


246 We have observed a clear trade-off between the power of an immunotherapy trial on the one hand, and the primary OS  
 247 endpoint, and correspondingly the data maturity, on the other. Luckily, the two are not entirely mutually exclusive: interim  
 248 analyses have been developed for ethical purposes to establish positive or harmful treatment effects early. However, there  
 249 is a catch: the necessity to control for multiple testing at each interim analysis lowers the significance threshold on the  
 250 final analysis to maintain the same overall type I error rate. This raises the question: “How many interim analyses should





**Figure 6: *In silico* trials guide decisions on OS endpoints and randomization ratios of upcoming immunotherapy trials.** (A-B) *In silico* trials can be used to find the optimal endpoint (panel 1) or randomization ratio (panel 2) of novel trials. (A) Since the survival curves in classical chemotherapy trials separate from the trial onset, the highest power – and optimal endpoint – is obtained at the end of the treatment interval (i.e., after six months in this example; see **Figure 4A**). Although less influential, a similar observation can be made for randomization ratios (study size panel 2: 300 patients). (B) Delayed curve separation in immunotherapy trials emphasizes that a premature final analysis of the primary OS endpoint is detrimental to the trial outcome. These trials permit validating the pre-specified survival outcomes of novel trials a priori. Commonly selected randomization ratios do not seem to be heavily influenced by immunotherapy-specific response patterns (study size panel 2: 1200 patient). Trial characteristics are similar to **Figure 4A/D**. All simulations performed using M1. Error bars: 95% CIs.

251 you plan, and when should you plan them?” Again, well-founded answers to such questions can be obtained with the help  
252 of *in silico* immunotherapy trials. To illustrate this, we used M1 to simulate 1000 immunotherapy trials with 1200 patients  
253 per trial, randomized 1:1 over immunotherapy with a strong treatment effect or a placebo (**Figure 7A**). In the absence  
254 of interim analyses, the vast majority of the trials are predicted to end up positive. Adding interim analyses (O’Brien-  
255 Fleming approach) to the equation induces a trade-off. On the one hand, increasing the number of equally-spaced interim  
256 analyses increases the probability of early detecting a positive treatment effect (e.g., approximately 60% of the trials are  
257 positive after 18 months in the case of three interim analyses; **Figure 7A**). On the other hand, the overall probability  
258 of ending up with a negative trial due to more stringent analyses (i.e., less power) also increases, especially in the case  
259 of immunotherapies with a weaker treatment effect ( $\pm 57\%$  without an interim analysis vs.  $\pm 63\%$  with three interim  
260 analyses; **Figure 7B**). In an actual trial, the latter needs to be corrected by including additional patients to maintain the  
261 pre-planned power. Furthermore, we observe that the timing of the interim analysis is crucial. Whereas an interim analysis  
262 at 18 months provides additional value to the trial, interim analyses before 16 months are predicted to be wasteful due to  
263 non-proportional hazards and less mature data. As a control, we simulated trials without any treatment effect. By design,  
264 approximately 95% of the trials should end up negative irrespective of the number of interim analyses, which indeed  
265 seemed to be the case (**Figure 7C**). Logically, the weaker the treatment effect, the higher the probability of erroneously  
266 finding a harmful treatment effect – a characteristic that the simulation also exhibits (**Figure 7B/C**).



267

268 **Figure 7: *A priori* scrutiny of the interim analysis plan to evaluate possible advantages and disadvantages of timed**  
 269 **additional analyses during the trial. (A)** In the case of immunotherapy with a potent effect, *in silico* trials help develop  
 270 a rationale for the timing of the interim analyses. In these simulations, while an interim analysis at 12 months might not  
 271 add value to the trial, analyses after 16 and 18 months, respectively, have a probability of approximately 24% and 40%  
 272 to lead to early stopping with a positive result. (B) Multiple interim analyses can reduce the probability of confirming  
 273 the desired treatment effect in case of a weak immunotherapy effect. (C) In the absence of any treatment effect (a control  
 274 scenario), the number of interim analyses does not heavily influence the trial outcome. Each trial simulation contains  
 275 1200 patients (randomization ratio 1:1) to ensure adequate power of the trial. Trials are analyzed with a proportions test  
 276 (Pearson's chi-squared test). Treatment effect (fold increase of the T cell killing rate): strong = 12, weak = 4, no effect =  
 277 0 (see Methods). All simulations were performed using M1.

## 278 Discussion

279 Over the past decade, tumor-immune dynamics have been investigated extensively with *in silico* models. In the early  
280 days of cancer immunotherapy, these modeling efforts focused – next to chemotherapy [37] – on cellular immunotherapy  
281 [38, 39]. More recently, the field has addressed ICI therapy (e.g., [33, 40, 41]). Models of tumor-immune dynamics  
282 have been applied to study pharmacokinetic and therapy dynamics (PK/PD), treatment effects (including mechanism(s)  
283 of action, optimizing dosing regimens), treatment combinations, toxicity, biomarker prediction, drug resistance, and drug  
284 discovery (see reviews on these topics [38, 42–47]). These extensive modeling efforts by the Mathematical Oncology  
285 community have created a rich and valuable methodological resource. The goal of the work described in this paper is to  
286 tap into this resource for the purpose of clinical trial design. Once parameterized, a mathematical model can predict likely  
287 outcomes of treatments for individual patients; using such a model for trial design requires considering heterogeneity  
288 between patients and translating these into likely survival curve shapes for each arm of the trial.

289 In this study, we leveraged mathematical models to perform cancer immunotherapy trials *in silico*, predicting survival  
290 and response profiles of various treatment regimens. Complementary to conventional design methods, *in silico* trials  
291 provide the ability to investigate the implications of a researcher’s biological (as opposed to statistical) hypotheses about a  
292 drug’s mechanism of action for the design, conduct, analysis, and outcome of clinical trials. When comparing the simulated  
293 outcomes to actual immunotherapy trial outcomes, we showed that *in silico* trials are suited to translate complex biological  
294 mechanisms (such as those observed during the treatment of patients with ICI) into realistic trial outcomes. Crucially,  
295 regardless of the model, the survival curves from these mechanism-based simulations reflected two pivotal components  
296 often found in immunotherapy trials: a delayed curve separation and a plateauing tail of the survival curve at later stages  
297 of the trial. In line with genuine immunotherapy trials, we find that these immunotherapy-specific response patterns differ  
298 considerably from chemotherapy. Our findings confirm that diversity in survival curves profoundly impacts the outcomes  
299 of immunotherapy trials [48]. Consequently, these features need to be considered when deciding on the sample size,  
300 endpoint, randomization ratio, and the number and timing of interim analyses of a novel cancer immunotherapy trial.

301 *In silico* clinical trials are gaining popularity in medicine. Such trials enable investigating, among others, how novel drugs,  
302 treatment schedules, dosing regimens, and inter-patient heterogeneity affect the outcome of a clinical trial [49]. *In silico*  
303 clinical studies have a wide range of applicability from pediatric infectious [50] and orphan diseases [51] to diabetes [52],  
304 inflammatory autoimmune diseases [53], traumatic injury [54], psychiatric illness [55], and cancer. In oncology, several *in*  
305 *silico* clinical trials involving chemotherapy and tyrosine kinase inhibitors have been performed [56], [57]. Moreover, with  
306 the onset of checkpoint inhibitors, *in silico* immunotherapy trials have gained interest, leading to trials with anti-CTLA-  
307 4-antibodies and anti-PD-(L)1 antibodies [58], [59], [60]. The common denominator in these trials is that they primarily  
308 center on dosing regimens and treatment schedules. Herein lies the main difference with our simulation approach: although  
309 the ‘key ingredients’ of these approaches are similar – they are based on a mathematical abstraction of a disease mechanism  
310 – our trials do not aim to optimize treatment schedules. Instead, we complement traditional design methodology by adding  
311 the means to predict key aspects of response and survival *a priori* to steer design decisions of novel immunotherapy trials.  
312 These trials differ from traditional trial design research in that these, often statistically-grounded, approaches simulate  
313 clinical trials based on population-level assumptions (e.g., with particular distributions of survival times, study durations,  
314 or with a specific censoring mechanism). Examples of such high-level simulation approaches include, but are certainly not  
315 limited to, studies aiming to calculate the sample size and power of clinical trials [61], [62], [63]. Since these methods lack  
316 a direct link to the underlying biological disease mechanism, interpreting their parameters for individual trial participants  
317 is difficult or even impossible. In contrast, *in silico* trials are founded on biological assumptions but then translate these  
318 assumptions into statistical concepts such as hazard ratios. In this manner, simulated trials encourage an interdisciplinary  
319 discussion about the design of an upcoming trial.

320 *In silico* clinical trials are applicable in several settings. First, they provide the means to verify clinical trial and treatment  
321 assumptions before investing extensive amounts of work and funds into the development and execution of a clinical trial  
322 and can, thereby, function as a proof of principle of the soundness of the hypotheses for an upcoming trial. Scrutiniz-  
323 ing each aspect of the trial design might lead to better design decisions and reduce unanticipated outcomes. Moreover,  
324 this mechanism-based approach does not necessitate a deep understanding of complex mathematical theorems; instead, it  
325 requires a biological understanding of a disease. This mechanistic basis is intuitive, which benefits the communication  
326 between clinical doctors and biomedical researchers on the one hand and statisticians and clinical trialists on the other.  
327 Additionally, *in silico* trials might serve as excellent educational tools. The ability to simulate a wide range – from basic  
328 to highly advanced – research questions can be exploited in teaching activities for entry-level clinicians to experienced  
329 trialists. A final implication, which holds for any trial simulation, is that they may provide some degree of insight when  
330 conventional clinical trials are unfeasible due to practical or ethical constraints (e.g., clinical trials in rare diseases, pedi-  
331 atrics, or critical care medicine).

332 Nonetheless, *in silico* clinical trials have to be considered in light of some limitations. The most critical limitation is  
333 universal to any scientific model, whether *in vitro*, *in vivo*, or computational: the immunotherapy trial outcomes depend  
334 heavily (if not entirely) on the biological assumptions of the model, meaning that incorrect interactions or erroneous  
335 parametrization of the model can lead to inaccurate predictions. The parameterization, in particular, might pose a problem:

336 given the often novel treatment mechanisms, data to fine-tune the parameters of the model accurately might be scarce. In  
337 these cases, the simulation itself can be used as a sensitivity analysis to assess to what extent a certain parameter range,  
338 or the structure of the model itself, influences the robustness of the predictions. Our use of three different models in this  
339 paper can be seen as such a type of sensitivity analysis; indeed, despite the major differences, it was reassuring to observe  
340 that the models often agreed when it came to the critical qualitative aspects of the predicted survival curves.

341 In addition, while ODE models can be rather simple and intuitive to understand, translating biological principles into an  
342 ODE model and implementing it into a simulation requires thorough knowledge of computational methods, potentially  
343 limiting its widespread applicability. To address these limitations, we have made our model implementations available  
344 as (1) an interactive website that can be used without installing any software and without any programming knowledge  
345 (<https://computational-immunology.org/models/immunotherapy-trials/>); (2) an R package allowing to run  
346 simulations without requiring knowledge of ODEs and their solutions.

347 In summary, *in silico* cancer immunotherapy trials offer a versatile approach to simulate immunotherapy trials based on  
348 biological assumptions. As a simulation tool, they facilitate the scrutiny of trial design decisions to optimize the probability  
349 of a successful immunotherapy trial and contribute to high-quality research for cancer patients.



## 350 Methods

### 351 Mechanism-based models of the tumor microenvironment

352 We implemented three ordinary differential equation (ODE) models of tumor-immune interactions: one from our previous  
353 work [27] and two by other authors [28, 29]. We first describe the common aspects of the models, then explain the  
354 differences and show the model equations. All models describe cancer onset and progression, and we initialize each  
355 model by seeding a single growing tumor cell. This tumor cell divides, leading to a proliferating mass of tumor cells.  
356 The parameter  $\rho$  controls the grows rate. Within the tumor microenvironment, an anti-tumor immune response induces  
357 cytotoxic T cells to kill tumor cells at rate  $\xi$ . Intratumoral T cells die at a rate  $\delta$ . In these models, the rate at which  
358 T cells are activated and/or proliferate depends initially on the tumor size: an early stage microscopic tumor presents  
359 fewer antigens than a larger – but still small – tumor. However, antigen presentation saturates as the tumor grows further  
360 (scaling factor  $T/(g + T)$  in Equations 3,4,3,9). Thus, four model parameters are shared between the models. Depending  
361 on the parameter values, it is possible that the immune response eliminates the tumor or that the tumor escapes and grows  
362 in an uncontrolled fashion.

363 We now discuss the model equations and parameters. In all models, we denote the number of tumor cells by  $T$  (Equations  
364 1,5,8) and the number of intratumoral T cells by  $I$  (Equations 2,6,9). Compared to their original versions, variables  
365 and parameters in the equations below have been renamed, and the units of some parameters scaled to make the models  
366 easily comparable.

367 **Model M1** is based on our previous work [27] and has the following equations:

$$\frac{dT}{dt} = \rho T^{\frac{3}{4}} - \xi I \frac{T}{1 + \frac{T}{h_I} + \frac{T}{h_T}} \quad (1)$$

$$\frac{dI}{dt} = m_S S - \delta I \quad (2)$$

$$\frac{dS}{dt} = \left( \frac{T}{g + T} \right) (\alpha_N N + p_S S) - m_S S \quad (3)$$

$$\frac{dN}{dt} = - \left( \frac{T}{g + T} \right) \alpha_N N \quad (4)$$

368 We implemented a tumor growth rate that is slower than exponential growth. This is a common modeling choice based  
369 on data and the biological premise that a growing tumor needs to sustain itself with nutrients. A common method to  
370 implement a sub-exponential growth, which we adopt here, is to raise the number of tumor cells to the 3/4th power to  
371 obtain the number of actively dividing cells [64]. We had previously modeled slightly faster-growing tumors using the  
372 less common power 4/5th [27]. However, given that the other two models already implement faster-growing tumors, we  
373 here use the more common, slower one. The killing of tumor cells is implemented using a double saturation model [65]  
374 parameterized as proposed by Gadhamsetty et al. [66] (Michaelis constants  $h_T$  and  $h_I$ ). The double saturation model  
375 reflects that T cell killing of tumor cells takes hours [67]. The immune cells within the tumor microenvironment originate  
376 from tumor-draining lymph nodes, where naive cytotoxic T cells ( $N$ , Equation 4) turn into activated T cells ( $S$ , activation  
377 rate  $\alpha_N$ ; Equation 4). Activated T cells proliferate at rate  $p_S$  and migrate to the tumor microenvironment to become  
378 infiltrating T cells ( $I$ ). The migration step leads to a slight delay between T cell activation and tumor cell killing on the  
379 order of days ( $m_S = 1\text{day}^{-1}$ ). If desired, the distinction between lymph node and tumor microenvironment sites could  
380 be removed for simplicity, given that the migration takes place on a faster timescale than the immune response.

381 **Model M2**, proposed by Tsur *et al.* [28], conceptually differs from M1 in five aspects. First, its tumor growth is unrestricted  
382 exponential. Second, the anti-tumor response saturates with increasing numbers of tumor cells but not with increasing  
383 numbers of T cells. Third, it explicitly represents antigen-presenting cells, called  $A$  (Equation 7), which are recruited at  
384 rate  $\alpha_A$  in response to the tumor growth. Fourth, its T cells do not proliferate but are produced at a capped rate. Fifth, it  
385 does not distinguish between T cells in the lymph node and intratumoral T cells. As mentioned above, this is likely not  
386 critical. The model equations are as follows:

$$\frac{dT}{dt} = \rho T - \xi I \frac{T}{1 + \frac{T}{h_T}} \quad (5)$$

$$\frac{dI}{dt} = \alpha_e A - \delta I \quad (6)$$

$$\frac{dA}{dt} = \alpha_A \frac{T}{g + T} - \delta_A A \quad (7)$$

387

388 **Model M3** was recently proposed by Bekker *et al.* [29]. It has two equations representing tumor cells and T cells. It  
389 resembles M2 in that tumor growth is initially exponential, but there is a maximum capacity for tumor cells (logistic

Model(s)	Symbol	Meaning	Unit
M1,M2,M3	$\rho$	Tumor proliferation rate	day <sup>-1</sup>
M1,M2,M3	$\delta$	T cell death rate	day <sup>-1</sup>
M1,M2,M3	$\xi$	T cell killing rate	day <sup>-1</sup> cell <sup>-1</sup>
M1,M2,M3	$g$	Amount of tumor cells at which antigen presentation is half-maximal	cell
M1,M2	$h_T$	Michaelis constant for tumor-dependent killing saturation	cell
M2,M3	$\alpha_A$	T cell influx	cell day <sup>-1</sup>
M1	$h_I$	Michaelis constant for T cell-dependent killing saturation	cell
M1	$m_s$	T cell migration rate	day <sup>-1</sup>
M1	$p_s$	Proliferation rate of T cells in lymph nodes	day <sup>-1</sup>
M1	$\alpha_N$	Activation rate of naïve T cells	day <sup>-1</sup>
M2	$\alpha_e$	Production rate of intratumoral T cells	day <sup>-1</sup>
M2	$\delta_A$	Death rate of antigen-presenting cells	day <sup>-1</sup>
M3	$p_I$	Proliferation rate of intratumoral T cells	day <sup>-1</sup>
M3	$\beta$	Maximum number of tumor cells the body can sustain	cell
M3	$\epsilon$	Rate at which tumor cells exhaust T cells	day <sup>-1</sup> cell <sup>-1</sup>

Table 1: **Overview of parameters used in the three models.** Four parameters are shared between all models. The number of parameters is the largest for M1 at 9 parameters, followed by M2 and M3 (8).

390 growth). Killing dynamics follow a “mass-action law” (i.e., there is no saturation of the killing rate like in M1 and M2).  
391 Further, it includes a term for tumor size-dependent T cell exhaustion. This modeling choice leads to oscillating numbers  
392 of T cells and tumor cells in many parameter regimes. The model equations are as follows:

$$\frac{dT}{dt} = \rho T(1 - T/\beta) - \xi IT \quad (8)$$

$$\frac{dI}{dt} = \alpha_A + p_I I \frac{T}{g + T} - \delta I - \epsilon IT \quad (9)$$

393

394 We emphasize that M3 has been presented by Bekker *et al.* [29] as an abstraction of the general mechanisms underlying  
395 immunotherapy similar to M1; neither model claims to fit specific time-resolved data. Nevertheless, we included it as we  
396 were interested in the impact of the different modeling choices.

## 397 Model parameters

398 **Table 1** shows an overview of the parameters in the three models. Four parameters appear in every model, but note that  
399 this does not necessarily mean that the parameters can be interpreted in the same way. For example, in a model where  
400 killing saturates in a scenario where there are many more tumor cells than T cells (M1 and M2), the same value of the  
401 killing rate will lead to less effective killing than in a model where there is no such saturation (M3). Other parameters are  
402 model-specific. To improve the inter-model comparability and reduce the potential for over-fitting, we left the parameters  
403 in all models fixed except the tumor growth rate  $\rho$ , which we varied to obtain heterogeneous patient populations.

404 Parameter values for M1 and M2 were taken from earlier publications [27,28], where the biological reasoning underlying  
405 these values is explained, and references are provided. Differences in model structure, and in experimental data being  
406 referred to, yield extensive variation in parameter values (**Table 2**). The variation in  $\rho$  is just a consequence of the different  
407 tumor growth models, which give a different meaning to the parameter in each model. Despite the differences, the values  
408 actually lead to comparable growth kinetics. The biggest quantitative differences are in the killing kinetics. M2’s killing  
409 rate  $\xi$  is three orders of magnitude smaller than M1’s, but M2 compensates for this by saturating the killing at a number of  
410 tumor cells that is five orders of magnitude higher than M1’s. Overall, the amount of cells being killed when the immune  
411 system is active and the tumor exceeds the diagnosis threshold is comparable across the models.

412 M3 was not explicitly parameterized by the authors [29]. Therefore, we set its parameters to the same values as in M1  
413 or M2 as much as possible. For instance, because both M2 and M3 contain essentially unrestricted exponential growth  
414 of the tumor cells until M3 approaches the carrying capacity, we used the value for the tumor growth rate in M2 for M3.  
415 For the killing rate, we used a value that gave similar killing speed as M1 for tumors containing  $10^9 - 10^{10}$  T cells. Note  
416 that due to the saturation term in M1, the killing is faster in M3 for larger tumors and slower for smaller tumors. Two  
417 parameters, the T cell exhaustion rate and the carrying capacity, were unique to M3. We set both to values that lead to  
418 a small influence of the corresponding terms on the simulation result and obtained comparable kinetics to the other two  
419 models at those parameter settings.

Parameter	$\rho$	$\delta$	$\xi$	$g$	$h_T$	$\alpha_A$	$h_I$	$m_S$	$p_S$	$\alpha_N$	$\alpha_e$	$\delta_A$	$p_I$	$\beta$	$\epsilon$
M1	5	.019	.001	10000000	571		571	1	1	.0025					
M2		.045	.178	.00000134	92330	60095000	2073.5				.8318	.231			
M3		.045	.019	.0000000001	10000000		2073.5						0.05	$1.1 \cdot 10^{12}$	$10^{-12}$

Table 2: **Fixed parameter values used in our simulations.** All values except  $\rho$  are taken from previous work, and are kept constant in all simulations. The value of  $\rho$  is allowed to vary between simulated patients to account for heterogeneity, and the distribution of  $\rho$  is fitted to real data. The values of  $\rho$  shown here were those used to generate Figure 2.

Parameter	$\rho$ (log <sub>10</sub> mean)	$\rho$ (log <sub>10</sub> sd)	chemotherapy effect	immunotherapy effect
M1	2.54	1.01	0.6	12.15
M2	-3.94	1.29	0.6	218.75
M3	-3.49	0.37	0.75	2.25

Table 3: **Fitted parameter values used in Figure 5–Figure 7.** The chemotherapy effect parameters were fixed and the other three parameters were then fitted using Approximate Bayesian Computation as described in the methods.

## 420 Simulating untreated disease, chemotherapy, and immunotherapy in individual patients

421 Using ODE models, we can implement different cancer immunotherapies in two general ways: (1) by changing model  
422 parameters; (2) by adding or removing cells at a certain time.

423 Using this ODE model, we simulated cancer development and disease trajectories in patients. We extensively varied the  
424 tumor properties (i.e., the tumor growth rate, the growth rate decline, and the decline decay rate) between patients to  
425 generate interpatient variation in disease courses.

426 Each patient is simulated from cancer onset (i.e., malignant transformation of the first cell) for up to ten years. As argued  
427 previously [27], we start from a diagnosis threshold of a tumor mass of  $65 \cdot 10^8$  cells, corresponding to the size at which  
428 common malignancies are diagnosed [68–70]. The lethal tumor burden is set to  $10^{12}$  tumor cells (a tumor volume of ap-  
429 proximately  $10.6 \text{ dm}^3$ ). Since we expect both thresholds to vary considerably between patients, depending, for example,  
430 on the timing of doctor visits or a tumor’s location, we implement them as random variables that change with every sim-  
431 ulation. Specifically, every threshold is drawn from a log-normal distribution with a  $4\sigma$  range of one order of magnitude.  
432 The upper  $2\sigma$  point (95.45% quantile) is set to  $65 \cdot 10^8$  for diagnosis and  $10^{12}$  for death.

433 Disease trajectories of patients with cancer can be steered with therapy. In our model, treatment is implemented by chang-  
434 ing the model parameters once the tumor exceeds the diagnosis threshold, as we assume this is when treatment starts.  
435 Given their prominent roles in many oncological treatment plans, we included immune checkpoint inhibitors (ICI) and  
436 chemotherapy in the models. Both treatments function through their primary modes of action. ICI are implemented by  
437 increasing the killing rate of cytotoxic T cells (i.e., the parameter  $\xi$ ) in M1 and M3. In M2, it is implemented by increasing  
438 the T cell activation rate  $\alpha_A$  and decreasing the death rate  $\delta$ ; for simplicity, we restrict this such that the fold increase of  
439  $\alpha_A$  equals the fold decrease of  $\delta$ . These changes are implemented directly after diagnosis and remain active for the rest of  
440 the simulation unless stated otherwise. The duration and potency of the ICI treatment (as measured by the magnitude of  
441 the change of the affected parameters) eventually determine patient outcome.

442 In patients treated with chemotherapy, the immune system is still present; however, it is not boosted (as is the case during  
443 ICI treatment). Hence, the T cells are not potent enough to curb tumor growth. We implement the cytotoxic capacity of  
444 chemotherapy in the models uniformly by reducing the tumor growth rate (parameter  $\rho$ ) to a smaller number. Again, the  
445 duration and potency (as measured by the reduction in tumor growth rate) determine patient outcome. By default, the  
446 treatment duration for ICI and chemotherapy are two years and six months, respectively.

## 447 Simulations of patient cohorts and parameter fitting

448 To generate heterogeneous patient populations, we draw each patient’s growth rate parameter  $\rho$  from a log-normal distri-  
449 bution. Depending on the parameter, the simulated patient’s tumor may clear spontaneously; such results are discarded  
450 (rejection sampling). When the tumor reaches the diagnosis threshold, we apply ICI, chemotherapy, a combination of  
451 chemotherapy and ICI, or we leave the patient untreated (i.e., a placebo treatment). Therefore, each patient cohort (Fig-  
452 ure 3) is characterized by two to four parameters: mean and standard deviation of the log tumor growth rate, immunother-  
453 apy treatment effect size, and chemotherapy treatment effect size. These two to four parameters can be fitted to a given  
454 dataset.

455 Due to the stochastic nature of our model, we used an approximate Bayesian computation / sequential Monte Carlo (ABC-  
456 SMC) algorithm [71] to fit the parameters. As the test statistic for ABC-SMC, we used the root mean squared differ-  
457 ence (RMSD) between model-predicted and data-estimated survival curves (i.e., Kaplan-Meier curves) evaluated for each  
458 month in a 2-year time window upon diagnosis. We set the sample size for generating the model-predicted survival curve

459 to the same number of patients that is contained in the data being fitted. **Figure 3** and **Supplementary Figure S1** show,  
460 for each model, the simulation that achieved the lowest RMSD to the target data during each ABC run.

461 We applied the ABC-SMC algorithm to all three patient cohorts shown in **Figure 4**. When examining the posterior distri-  
462 butions of the parameters, we found that a wide range of chemotherapy effect values achieved comparable RMSD values  
463 for each model – which is not surprising, given that a higher baseline growth rate combined with a higher chemotherapy  
464 effect leads to similar predicted tumor growth as a lower baseline growth rate combined with a lower chemotherapy effect.  
465 We therefore performed a further set of fits to the CA184-024 data where we kept the chemotherapy effect values fixed at  
466 0.6 for M1 and M2 and at 0.75 for M3, respectively – values that were chosen to obtain comparable and realistic impacts  
467 of chemotherapy on the 2-year OS curves (**Figure 5A**), and were plausible given the posterior distributions. We then  
468 again fitted the remaining three parameters to the CA184-024 data using ABC-SMC. By estimating the mode of the joint  
469 posterior distribution using kernel density smoothing, we obtained the parameter values shown in Table 3.

## 470 **Simulating late-stage immunotherapy trials**

471 Late-stage (i.e., phase III) clinical trials traditionally contain two arms: a control arm and a treatment arm. The control arm  
472 can be a placebo (i.e., untreated) or a standard of care therapy. To construct phase III *in silico* immunotherapy trials, we  
473 extended the simulations with treatment cohorts (mono-chemotherapy, mono-immunotherapy, chemoimmunotherapy, or  
474 induction chemotherapy followed by immunotherapy). These cohorts facilitate the comparison between various treatment  
475 regimens. The treatment cohort uses the same baseline distribution of tumor growth parameters as the control cohort.  
476 Upon reaching the diagnosis threshold, up to two different treatments are applied in each arm; patients can be treated with  
477 chemotherapy, ICI, combination therapy, or left untreated (as described above). Unless otherwise specified, the baseline  
478 distribution of tumor growth parameters was derived from the most mature, digitized data from the CA184-024 trial, as  
479 shown below [35].

480 The primary endpoint of the trials is the 2-year OS. Given the absence of accrual times in *in silico* trials, the trial duration  
481 equals two years, providing each virtual patient with 24 months of follow-up at the time of analysis. If the OS endpoint  
482 is not reached for a patient (i.e., the patient’s tumor burden does not reach the lethal volume within the time frame of the  
483 simulated trial), the patient is considered censored for the endpoint and regarded as such in subsequent analyses.

## 484 **Power and interim analysis simulations**

485 To illustrate how the analysis method can affect the outcome of immunotherapy trials, we use several simulation approaches  
486 to calculate the power of trials. Power simulations were performed as follows: a varying number of clinical trials were  
487 simulated per data point. The survival data from each trial was analyzed with a log-rank test (dependent on the proportional  
488 hazard assumption) or proportions test (Pearson’s chi-squared test; independent of the proportional hazard assumption),  
489 and we counted the number of positive trials (defined as  $p < 0.05$ ). The percentage of positive trials indicates the power  
490 of the trial. A harmful trial is defined as a positive trial with an effect size that favours untreated patients.

## 491 **Data digitization & reconstruction**

492 For some survival curves, the raw data was not available. Therefore, we extracted data points from the Kaplan-Meier  
493 curves with WebPlotDigitizer 4.6 (<https://apps.automeris.io/wpd/>), and individual patient data was reconstructed  
494 with the IPDfromKM package in R.

## 495 **Analyses**

496 Analyses and visualizations were performed in R. The complete list of R packages used throughout this manuscript is  
497 provided in **Supplementary Table S1**. The R code used to perform all analyses is available at [https://github.com/  
498 jtextor/insilico-trials](https://github.com/jtextor/insilico-trials).

499 **Data availability**

500 All simulated data used to generate the figures is available at this paper's GitHub repository at [https://github.com/](https://github.com/jtextor/insilico-trials)  
501 [jtextor/insilico-trials](https://github.com/jtextor/insilico-trials). The digitized survival data from the CA184-024 and CheckMate 066 trials is also available  
502 at the same repository.

503 **Code availability**

504 C++ code that implements models M1, M2 and M3, and an R package that wraps the C++ code using Rcpp is available at  
505 this paper's GitHub repository at <https://github.com/jtextor/insilico-trials/models/TumorImmuneModels/>.  
506 The R code used to perform all analyses and generate all plots is also available at the same repository. An interactive, web-  
507 based implementation of our models, written in Javascript and HTML, is available at [https://computational-immunology.](https://computational-immunology.org/models/immunotherapy-trials/)  
508 [org/models/immunotherapy-trials/](https://computational-immunology.org/models/immunotherapy-trials/).



## References

- 509
- 510 [1] Upadhaya S, Hubbard-Lucey VM, and Yu JX. Immuno-oncology drug development forges on despite covid-19.  
511 *Nature Reviews Drug Discovery*, 19(11):751–752, 2020. doi:[10.1038/d41573-020-00166-1](https://doi.org/10.1038/d41573-020-00166-1).
- 512 [2] Dowden H and Munro J. Trends in clinical success rates and therapeutic focus. *Nature Reviews Drug Discovery*,  
513 18(7):495–496, 2019. doi:[10.1038/d41573-019-00074-z](https://doi.org/10.1038/d41573-019-00074-z).
- 514 [3] Wong CH, Siah KW, and Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics*,  
515 20(2):273–286, 2018. doi:[10.1093/biostatistics/kxx069](https://doi.org/10.1093/biostatistics/kxx069).
- 516 [4] BIO QA Informa Pharma Intelligence. Clinical development success rates and contributing factors.  
517 <https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020>, 2021.
- 518 [5] Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, and Kesselheim AS. Failure of investigational  
519 drugs in late-stage clinical development and publication of trial results. *JAMA Internal Medicine*, 176(12):1826,  
520 2016. doi:[10.1001/jamainternmed.2016.6008](https://doi.org/10.1001/jamainternmed.2016.6008).
- 521 [6] de Miguel M and Calvo E. Clinical challenges of immune checkpoint inhibitors. *Cancer Cell*, 38(3):326–333, 2020.  
522 doi:[10.1016/j.ccell.2020.07.004](https://doi.org/10.1016/j.ccell.2020.07.004).
- 523 [7] Li A and Bergan RC. Clinical trial design: Past, present, and future in the context of big data and precision medicine.  
524 *Cancer*, 126(22):4838–4846, 2020. doi:[10.1002/cncr.33205](https://doi.org/10.1002/cncr.33205).
- 525 [8] Cousin S, Seneschal J, and Italiano A. Toxicity profiles of immunotherapy. *Pharmacology & Therapeutics*, 181:91–  
526 100, 2018. doi:[10.1016/j.pharmthera.2017.07.005](https://doi.org/10.1016/j.pharmthera.2017.07.005).
- 527 [9] Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi  
528 FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, and de Vries EGE. irrecist:  
529 guidelines for response criteria for use in trials testing immunotherapeutics. *The Lancet Oncology*, 18(3):e143–e152,  
530 2017. doi:[10.1016/s1470-2045\(17\)30074-8](https://doi.org/10.1016/s1470-2045(17)30074-8).
- 531 [10] Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, and  
532 Wolchok J. Improved endpoints for cancer immunotherapy trials. *JNCI Journal of the National Cancer Institute*,  
533 102(18):1388–1397, 2010. doi:[10.1093/jnci/djq310](https://doi.org/10.1093/jnci/djq310).
- 534 [11] Chen TT. Statistical issues and challenges in immuno-oncology. *Journal for ImmunoTherapy of Cancer*, 1(1), 2013.  
535 doi:[10.1186/2051-1426-1-18](https://doi.org/10.1186/2051-1426-1-18).
- 536 [12] Mick R and Chen TT. Statistical challenges in the design of late-stage cancer immunotherapy studies. *Cancer*  
537 *Immunology Research*, 3(12):1292–1298, 2015. doi:[10.1158/2326-6066.cir-15-0260](https://doi.org/10.1158/2326-6066.cir-15-0260).
- 538 [13] Rahman R, Fell G, Ventz S, Arfé A, Vanderbeek AM, Trippa L, and Alexander BM. Deviation from the propor-  
539 tional hazards assumption in randomized phase 3 clinical trials in oncology: Prevalence, associated factors, and  
540 implications. *Clinical Cancer Research*, 25(21):6339–6345, 2019. doi:[10.1158/1078-0432.ccr-18-3999](https://doi.org/10.1158/1078-0432.ccr-18-3999).
- 541 [14] Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer  
542 U, Rhee I, Fine G, Winslow N, Chen DS, and Wolchok JD. Immune-modified response evaluation criteria in solid  
543 tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy. *Journal of Clinical*  
544 *Oncology*, 36(9):850–858, 2018. doi:[10.1200/jco.2017.75.1644](https://doi.org/10.1200/jco.2017.75.1644).
- 545 [15] Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey  
546 R, and Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response  
547 criteria. *Clinical Cancer Research*, 15(23):7412–7420, 2009. doi:[10.1158/1078-0432.ccr-09-1624](https://doi.org/10.1158/1078-0432.ccr-09-1624).
- 548 [16] Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQ, and Forde PM. Immuno-  
549 oncology trial endpoints: Capturing clinically meaningful activity. *Clinical Cancer Research*, 23(17):4959–4969,  
550 2017. doi:[10.1158/1078-0432.ccr-16-3065](https://doi.org/10.1158/1078-0432.ccr-16-3065).
- 551 [17] Mushti SL, Mulkey F, and Sridhara R. Evaluation of overall response rate and progression-free survival as potential  
552 surrogate endpoints for overall survival in immunotherapy trials. *Clinical Cancer Research*, 24(10):2268–2275,  
553 2018. doi:[10.1158/1078-0432.ccr-17-1902](https://doi.org/10.1158/1078-0432.ccr-17-1902).
- 554 [18] Chen TT. Milestone survival: A potential intermediate endpoint for immune checkpoint inhibitors. *Journal of the*  
555 *National Cancer Institute*, 107(9):d1v156, 2015. doi:[10.1093/jnci/djv156](https://doi.org/10.1093/jnci/djv156).
- 556 [19] Kaufman HL, Andtbacka RHI, Collichio FA, Wolf M, Zhao Z, Shilkrut M, Puzanov I, and Ross M. Durable response  
557 rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. *Journal for ImmunoTher-*  
558 *apy of Cancer*, 5(1), 2017. doi:[10.1186/s40425-017-0276-8](https://doi.org/10.1186/s40425-017-0276-8).

- 559 [20] Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A, and Peters S. Development of tumor mutation  
560 burden as an immunotherapy biomarker: utility for the oncology clinic. *Annals of Oncology*, 30(1):44–56, 2019.  
561 doi:[10.1093/annonc/mdy495](https://doi.org/10.1093/annonc/mdy495).
- 562 [21] Dudley JC, Lin MT, Le DT, and Eshleman JR. Microsatellite instability as a biomarker for pd-1 blockade. *Clinical  
563 Cancer Research*, 22(4):813–820, 2016. doi:[10.1158/1078-0432.ccr-15-1678](https://doi.org/10.1158/1078-0432.ccr-15-1678).
- 564 [22] Patel SP and Kurzrock R. Pd-1l expression as a predictive biomarker in cancer immunotherapy. *Molecular Cancer  
565 Therapeutics*, 14(4):847–856, 2015. doi:[10.1158/1535-7163.mct-14-0983](https://doi.org/10.1158/1535-7163.mct-14-0983).
- 566 [23] Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, and Sinicrope FA. Tumor mutational burden as a predictive  
567 biomarker in solid tumors. *Cancer Discovery*, 10(12):1808–1825, 2020. doi:[10.1158/2159-8290.cd-20-0522](https://doi.org/10.1158/2159-8290.cd-20-0522).
- 568 [24] Chen TT. Designing late-stage randomized clinical trials with cancer immunotherapy: Can we make it simpler?  
569 *Cancer Immunology Research*, 6(3):250–254, 2018. doi:[10.1158/2326-6066.cir-17-0465](https://doi.org/10.1158/2326-6066.cir-17-0465).
- 570 [25] Royston P and Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and  
571 analysis of randomized trials with a time-to-event outcome. *BMC Medical Research Methodology*, 13(1), 2013.  
572 doi:[10.1186/1471-2288-13-152](https://doi.org/10.1186/1471-2288-13-152).
- 573 [26] Xu Z, Zhen B, Park Y, and Zhu B. Designing therapeutic cancer vaccine trials with delayed treatment effect. *Statistics  
574 in Medicine*, 36(4):592–605, 2016. doi:[10.1002/sim.7157](https://doi.org/10.1002/sim.7157).
- 575 [27] Creemers JHA, Lesterhuis WJ, Mehra N, Gerritsen WR, Figdor CG, de Vries IJM, and Textor J. A tipping point in  
576 cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. *Journal  
577 for ImmunoTherapy of Cancer*, 9(5):e002032, 2021. doi:[10.1136/jitc-2020-002032](https://doi.org/10.1136/jitc-2020-002032).
- 578 [28] Tsur N, Kogan Y, Rehm M, and Agur Z. Response of patients with melanoma to immune checkpoint blockade – in-  
579 sights gleaned from analysis of a new mathematical mechanistic model. *Journal of Theoretical Biology*, 485:110033,  
580 2020. doi:[10.1016/j.jtbi.2019.110033](https://doi.org/10.1016/j.jtbi.2019.110033).
- 581 [29] Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, and Enderling H. Rethinking the im-  
582 munotherapy numbers game. *Journal for ImmunoTherapy of Cancer*, 10(7):e005107, 2022. doi:[10.1136/jitc-2022-  
583 005107](https://doi.org/10.1136/jitc-2022-005107).
- 584 [30] Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh  
585 SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima  
586 H, Kang YK, and Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal  
587 junction cancer (ATTRACTION-2): 2-year update data. *Gastric Cancer*, 23(3):510–519, 2019. doi:[10.1007/s10120-  
588 019-01034-7](https://doi.org/10.1007/s10120-019-01034-7).
- 589 [31] Hellmann MD, Paz-Ares L, Caro RB, Zurawski B, Kim SW, Costa EC, Park K, Alexandru A, Lupinacci L, de la  
590 Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brah-  
591 mer JR, O’Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, and Rama-  
592 lingam SS. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. *New England Journal of Medicine*,  
593 381(21):2020–2031, 2019. doi:[10.1056/nejmoa1910231](https://doi.org/10.1056/nejmoa1910231).
- 594 [32] Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S,  
595 Oulkhair Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A,  
596 Baudelet C, and Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma  
597 (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. *The Lancet*, 397(10272):375–386, 2021.  
598 doi:[10.1016/s0140-6736\(20\)32714-8](https://doi.org/10.1016/s0140-6736(20)32714-8).
- 599 [33] Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, Lotem M, and Agur Z. Predicting response to  
600 pembrolizumab in metastatic melanoma by a new personalization algorithm. *Journal of Translational Medicine*,  
601 17(1), 2019. doi:[10.1186/s12967-019-2081-2](https://doi.org/10.1186/s12967-019-2081-2).
- 602 [34] Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, and Klatt NE.  
603 Prospective evaluation of prognostic variables from patient-completed questionnaires. north central cancer treatment  
604 group. *Journal of Clinical Oncology*, 12(3):601–607, 1994. doi:[10.1200/jco.1994.12.3.601](https://doi.org/10.1200/jco.1994.12.3.601).
- 605 [35] Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT,  
606 Tschaika M, and Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who  
607 received ipilimumab plus dacarbazine in a phase III trial. *Journal of Clinical Oncology*, 33(10):1191–1196, 2015.  
608 doi:[10.1200/jco.2014.56.6018](https://doi.org/10.1200/jco.2014.56.6018).
- 609 [36] Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Giacomo AMD, Mortier L, Hassel JC, Rutkowski P,  
610 McNeil C, Kalinka-Warzocho E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni  
611 V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, and

- 612 Atkinson V. Survival outcomes in patients with previously untreated braf wild-type advanced melanoma treated  
613 with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial. *JAMA Oncology*, 5(2):187, 2019.  
614 doi:[10.1001/jamaoncol.2018.4514](https://doi.org/10.1001/jamaoncol.2018.4514).
- 615 [37] Agur Z. From the evolution of toxin resistance to virtual clinical trials: the role of mathematical models in oncology.  
616 *Future Oncology*, 6(6):917–927, 2010. doi:[10.2217/fon.10.61](https://doi.org/10.2217/fon.10.61).
- 617 [38] Gupta SK, Jaitly T, Schmitz U, Schuler G, Wolkenhauer O, and Vera J. Personalized cancer immunotherapy using  
618 systems medicine approaches. *Briefings in Bioinformatics*, 17(3):453–467, 2015. doi:[10.1093/bib/bbv046](https://doi.org/10.1093/bib/bbv046).
- 619 [39] Walker R and Enderling H. From concept to clinic: Mathematically informed immunotherapy. *Current Problems in*  
620 *Cancer*, 40(1):68–83, 2016. doi:[10.1016/j.currprobcancer.2015.10.004](https://doi.org/10.1016/j.currprobcancer.2015.10.004).
- 621 [40] Butner JD, Elganainy D, Wang CX, Wang Z, Chen SH, Esnaola NF, Pasqualini R, Arap W, Hong DS, Welsh J, Koay  
622 EJ, and Cristini V. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint  
623 inhibitor immunotherapy. *Science Advances*, 6(18), 2020. doi:[10.1126/sciadv.aay6298](https://doi.org/10.1126/sciadv.aay6298).
- 624 [41] Coletti R, Pugliese A, and Marchetti L. Modeling the effect of immunotherapies on human castration-resistant  
625 prostate cancer. *Journal of Theoretical Biology*, 509:110500, 2021. doi:[10.1016/j.jtbi.2020.110500](https://doi.org/10.1016/j.jtbi.2020.110500).
- 626 [42] Konstorum A, Vella AT, Adler AJ, and Laubenbacher RC. Addressing current challenges in cancer immunotherapy  
627 with mathematical and computational modelling. *Journal of The Royal Society Interface*, 14(131):20170150, 2017.  
628 doi:[10.1098/rsif.2017.0150](https://doi.org/10.1098/rsif.2017.0150).
- 629 [43] Brown LV, Gaffney EA, Wagg J, and Coles MC. Applications of mechanistic modelling to clinical and experimental  
630 immunology: an emerging technology to accelerate immunotherapeutic discovery and development. *Clinical and*  
631 *Experimental Immunology*, 193(3):284–292, 2018. doi:[10.1111/cei.13182](https://doi.org/10.1111/cei.13182).
- 632 [44] Yates JW, Byrne H, Chapman SC, Chen T, Cucurull-Sanchez L, Delgado-SanMartin J, Di Veroli G, Dovedi SJ,  
633 Dunlop C, Jena R, Jodrell D, Martin E, Mercier F, Ramos-Montoya A, Struemper H, and Vicini P. Opportunities  
634 for quantitative translational modeling in oncology. *Clinical Pharmacology & Therapeutics*, 108(3):447–457, 2020.  
635 doi:[10.1002/cpt.1963](https://doi.org/10.1002/cpt.1963).
- 636 [45] Agur Z, Halevi-Tobias K, Kogan Y, and Shlagman O. Employing dynamical computational models for  
637 personalizing cancer immunotherapy. *Expert Opinion on Biological Therapy*, 16(11):1373–1385, 2016.  
638 doi:[10.1080/14712598.2016.1223622](https://doi.org/10.1080/14712598.2016.1223622).
- 639 [46] dePillis LG, Eladdadi A, and Radunskaya AE. Modeling cancer-immune responses to therapy. *Journal of Pharma-*  
640 *cokinetics and Pharmacodynamics*, 41(5):461–478, 2014. doi:[10.1007/s10928-014-9386-9](https://doi.org/10.1007/s10928-014-9386-9).
- 641 [47] Craig M, Jenner AL, Namgung B, Lee LP, and Goldman A. Engineering in medicine to address the challenge of  
642 cancer drug resistance: From micro- and nanotechnologies to computational and mathematical modeling. *Chemical*  
643 *Reviews*, 121(6):3352–3389, 2020. doi:[10.1021/acs.chemrev.0c00356](https://doi.org/10.1021/acs.chemrev.0c00356).
- 644 [48] Chen TT. Predicting analysis times in randomized clinical trials with cancer immunotherapy. *BMC Medical Research*  
645 *Methodology*, 16(1), 2016. doi:[10.1186/s12874-016-0117-3](https://doi.org/10.1186/s12874-016-0117-3).
- 646 [49] Alfonso S, Jenner AL, and Craig M. Translational approaches to treating dynamical diseases through in silico clinical  
647 trials. *Chaos: An Interdisciplinary Journal of Nonlinear Science*, 30(12):123128, 2020. doi:[10.1063/5.0019556](https://doi.org/10.1063/5.0019556).
- 648 [50] Valitalo PAJ, van den Anker JN, Allegaert K, de Cock RFW, de Hoog M, Simons SHP, Mouton JW, and Knibbe  
649 CAJ. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. *Journal*  
650 *of Antimicrobial Chemotherapy*, 70(7):2074–2077, 2015. doi:[10.1093/jac/dkv052](https://doi.org/10.1093/jac/dkv052).
- 651 [51] Carlier A, Vasilevich A, Marechal M, de Boer J, and Geris L. In silico clinical trials for pediatric orphan diseases.  
652 *Scientific Reports*, 8(1), 2018. doi:[10.1038/s41598-018-20737-y](https://doi.org/10.1038/s41598-018-20737-y).
- 653 [52] Klinke DJ. Integrating epidemiological data into a mechanistic model of type 2 diabetes: Validating the prevalence  
654 of virtual patients. *Annals of Biomedical Engineering*, 36(2):321–334, 2007. doi:[10.1007/s10439-007-9410-y](https://doi.org/10.1007/s10439-007-9410-y).
- 655 [53] Schmidt BJ, Casey FP, Paterson T, and Chan JR. Alternate virtual populations elucidate the type i interferon signature  
656 predictive of the response to rituximab in rheumatoid arthritis. *BMC Bioinformatics*, 14(1), 2013. doi:[10.1186/1471-2105-14-221](https://doi.org/10.1186/1471-2105-14-221).
- 657  
658 [54] Brown D, Namas RA, Almahmoud K, Zaaqoq A, Sarkar J, Barclay DA, Yin J, Ghuma A, Abboud A, Con-  
659 stantine G, Nieman G, Zamora R, Chang SC, Billiar TR, and Vodovotz Y. Trauma in silico: Individual-  
660 specific mathematical models and virtual clinical populations. *Science Translational Medicine*, 7(285), 2015.  
661 doi:[10.1126/scitranslmed.aaa3636](https://doi.org/10.1126/scitranslmed.aaa3636).

- 662 [55] Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, and Russu A. Dosing and switching  
663 strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population phar-  
664 macokinetic modeling and simulation, and clinical trial data. *CNS Drugs*, 31(4):273–288, 2017. doi:[10.1007/s40263-](https://doi.org/10.1007/s40263-017-0416-1)  
665 [017-0416-1](https://doi.org/10.1007/s40263-017-0416-1).
- 666 [56] Pérez-García VM, Ayala-Hernández LE, Belmonte-Beitia J, Schucht P, Murek M, Raabe A, and Sepúlveda J. Com-  
667 putational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas. *PLOS Com-*  
668 *putational Biology*, 15(7):e1006778, 2019. doi:[10.1371/journal.pcbi.1006778](https://doi.org/10.1371/journal.pcbi.1006778).
- 669 [57] Fassoni AC, Baldow C, Roeder I, and Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective  
670 as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. *Haematologica*,  
671 103(11):1825–1834, 2018. doi:[10.3324/haematol.2018.194522](https://doi.org/10.3324/haematol.2018.194522).
- 672 [58] Jafarnejad M, Gong C, Gabrielson E, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, and Popel AS. A  
673 computational model of neoadjuvant PD-1 inhibition in non-small cell lung cancer. *The AAPS Journal*, 21(5), 2019.  
674 doi:[10.1208/s12248-019-0350-x](https://doi.org/10.1208/s12248-019-0350-x).
- 675 [59] Milberg O, Gong C, Jafarnejad M, Bartelink IH, Wang B, Vicini P, Narwal R, Roskos L, and Popel AS. A QSP model  
676 for predicting clinical responses to monotherapy, combination and sequential therapy following CTLA-4, PD-1, and  
677 PD-11 checkpoint blockade. *Scientific Reports*, 9(1), 2019. doi:[10.1038/s41598-019-47802-4](https://doi.org/10.1038/s41598-019-47802-4).
- 678 [60] Wang H, Milberg O, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Santa-Maria CA, and Popel AS. In  
679 silico simulation of a clinical trial with anti-ctla-4 and anti-pd-11 immunotherapies in metastatic breast cancer using  
680 a systems pharmacology model. *Royal Society Open Science*, 6(5):190366, 2019. doi:[10.1098/rsos.190366](https://doi.org/10.1098/rsos.190366).
- 681 [61] Bang H, Jung SH, and George SL. Sample size calculation for simulation-based multiple-testing procedures. *Journal*  
682 *of Biopharmaceutical Statistics*, 15(6):957–967, 2005. doi:[10.1080/10543400500265710](https://doi.org/10.1080/10543400500265710).
- 683 [62] Doostfateme M, Ayatollah SMT, and Jafari P. Power and sample size calculations in clinical trials with patient-  
684 reported outcomes under equal and unequal group sizes based on graded response model: A simulation study. *Value*  
685 *in Health*, 19(5):639–647, 2016. doi:[10.1016/j.jval.2016.03.1857](https://doi.org/10.1016/j.jval.2016.03.1857).
- 686 [63] Wilson DT, Hooper R, Brown J, Farrin AJ, and Walwyn RE. Efficient and flexible simulation-based sample size  
687 determination for clinical trials with multiple design parameters. *Statistical Methods in Medical Research*, 30(3):799–  
688 815, 2020. doi:[10.1177/0962280220975790](https://doi.org/10.1177/0962280220975790).
- 689 [64] West GB, Brown JH, and Enquist BJ. A general model for ontogenetic growth. *Nature*, 413(6856):628–631, 2001.  
690 doi:[10.1038/35098076](https://doi.org/10.1038/35098076).
- 691 [65] Borghans JAM, de Boer RJ, and Segel LA. Extending the quasi-steady state approximation by changing variables.  
692 *Bulletin of Mathematical Biology*, 58(1):43–63, 1996. doi:[10.1007/bf02458281](https://doi.org/10.1007/bf02458281).
- 693 [66] Gadhamsetty S, Marée A, Beltman J, and de Boer R. A general functional response of cytotoxic t lymphocyte-  
694 mediated killing of target cells. *Biophysical Journal*, 106(8):1780–1791, 2014. doi:[10.1016/j.bpj.2014.01.048](https://doi.org/10.1016/j.bpj.2014.01.048).
- 695 [67] Weigel B, den Boer AT, Wagena E, Broen K, Dolstra H, de Boer RJ, Figdor CG, Textor J, and Friedl P. Cytotoxic  
696 t cells are able to efficiently eliminate cancer cells by additive cytotoxicity. *Nature Communications*, 12(1), 2021.  
697 doi:[10.1038/s41467-021-25282-3](https://doi.org/10.1038/s41467-021-25282-3).
- 698 [68] Moreno CC, Mittal PK, Sullivan PS, Rutherford R, Staley CA, Cardona K, Hawk NN, Dixon WT, Kitajima HD, Kang  
699 J, Small WC, Oshinski J, and Votaw JR. Colorectal cancer initial diagnosis: Screening colonoscopy, diagnostic  
700 colonoscopy, or emergent surgery, and tumor stage and size at initial presentation. *Clinical Colorectal Cancer*,  
701 15(1):67–73, 2016. doi:[10.1016/j.clcc.2015.07.004](https://doi.org/10.1016/j.clcc.2015.07.004).
- 702 [69] Zastrow S, Phuong A, von Bar I, Novotny V, Hakenberg OW, and Wirth MP. Primary tumor size in renal cell cancer  
703 in relation to the occurrence of synchronous metastatic disease. *Urologia Internationalis*, 92(4):462–467, 2014.  
704 doi:[10.1159/000356325](https://doi.org/10.1159/000356325).
- 705 [70] Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penniment MG, Vinod SK, Krawitz HE, Joseph DJ,  
706 Wheeler GC, and McClure BE. The complex relationship between lung tumor volume and survival in patients with  
707 non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study  
708 of the trans-tasman radiation oncology group (TROG 99.05). *Radiotherapy and Oncology*, 106(3):305–311, 2013.  
709 doi:[10.1016/j.radonc.2012.12.003](https://doi.org/10.1016/j.radonc.2012.12.003).
- 710 [71] Sisson SA, Fan Y, and Tanaka MM. Sequential monte carlo without likelihoods. *Proceedings of the National*  
711 *Academy of Sciences*, 104(6):1760–1765, 2007. doi:[10.1073/pnas.0607208104](https://doi.org/10.1073/pnas.0607208104).
- 712 [72] Paola Reboras AS and Reilly M. *bshazard: Nonparametric Smoothing of the Hazard Function*, 2018. R package  
713 version 1.1.



- 714 [73] Wickham H, François R, Henry L, and Müller K. *dplyr: A Grammar of Data Manipulation*, 2022. R package version  
715 1.0.10.
- 716 [74] Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York, 2016.
- 717 [75] Sjoberg D. *ggsankey: Sankey, Alluvial and Sankey Bump Plots*, 2022. R package version 0.0.99999.
- 718 [76] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing,  
719 Vienna, Austria, 2022.
- 720 [77] Liu N and Lee J. *IPDfromKM: Map Digitized Survival Curves Back to Individual Patient Data*, 2020. R package  
721 version 0.1.10.
- 722 [78] Duong T. *ks: Kernel Smoothing*, 2022. R package version 1.13.5.
- 723 [79] Casper C, Cook T, and Perez. OA. *ldbounds: Lan-DeMets Method for Group Sequential Boundaries*, 2022. R  
724 package version 2.0.0. Based on FORTRAN program ld98.
- 725 [80] Eddelbuettel D and François R. Rcpp: Seamless R and C++ integration. *Journal of Statistical Software*, 40(8):1–18,  
726 2011. doi:[10.18637/jss.v040.i08](https://doi.org/10.18637/jss.v040.i08).
- 727 [81] Terry M. Therneau and Patricia M. Grambsch. *Modeling Survival Data: Extending the Cox Model*. Springer, New  
728 York, 2000.
- 729 [82] Kassambara A, Kosinski M, and Biecek P. *survminer: Drawing Survival Curves using 'ggplot2'*, 2021. R package  
730 version 0.4.9.



731 **List of abbreviations**

732 ICI: immune checkpoint inhibitor; NCCTG: North Central Cancer Treatment Group; ODE: ordinary differential equation;  
733 OS: overall survival; PHA: proportional hazard assumption.

734 **Declarations**

735 **Ethics approval and consent to participate**

736 Not applicable.

737 **Consent for publication**

738 Not applicable.

739 **Competing interests**

740 Not applicable.

741 **Funding**

742 JC was funded by the Radboudumc. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant.  
743 IV received an NWO-Vici grant (918.14.655). JT and AA were supported by a Young Investigator Grant (10620) from  
744 the Dutch Cancer Society. JT and GS were also supported by NWO grant VI.Vidi.192.084.


745 **Author contributions**

746 JHAC and JT conceived this study. JHAC, AA and JT performed the experiments. JHAC and JT wrote the manuscript.  
747 All authors provided feedback on the manuscript and reviewed the manuscript prior to submission.


748 **Acknowledgements**

749 We thank Shabaz Sultan for his help with implementing the web-based frontend for performing simulations.


750 **Supplementary Figures**




Supplementary Figure S1: Fits of models M2 and M3 to three survival datasets from clinical trials (compare to **Figure 3**).




Supplementary Figure S2: *In silico* chemotherapy trial that approximately fulfills the proportional hazards assumption.



Supplementary Figure S3: Predicted immunotherapy trial survival curves for model M2 based on its fit to the CA184-024 trial data.



Supplementary Figure S4: Predicted immunotherapy trial survival curves for model M3 based on its fit to the CA184-024 trial data.



Supplementary Figure S5: Power analyses for chemotherapy vs. placebo and chemoimmunotherapy vs. immunotherapy trials using all three models.



R package	Reference	Version	Source
bshazard	[72]	1.1	CRAN
dplyr	[73]	1.0.10	CRAN
ggplot2	[74]	3.3.6	CRAN
ggsankey	[75]	0.0.99999	<a href="https://github.com/davidsjoberg/ggsankey">github.com/davidsjoberg/ggsankey</a>
grid	[76]	4.2.0	part of R 4.2.0
IPDfromKM	[77]	0.1.10	CRAN
ks	[78]	1.13.5	CRAN
ldbounds	[79]	2.0.0	CRAN
Rccp	[80]	1.0.9	CRAN
survival	[81]	3.3-1	CRAN
survminer	[82]	0.4.9	CRAN

Supplementary Table S1: R packages used in this manuscript with references and versions.